The efficacy and safety of VALTREX for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-1−infected patients have not been established.VALTREX is indicated for the reduction of transmission of genital herpes in immunocompetent adults. Your dose of VALTREX and length of treatment will depend on the type
Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).The recommended dosage of VALTREX for treatment of chickenpox in immunocompetent pediatric patients aged 2 to less than 18 years is 20 mg/kg administered 3 times daily for 5 days. Other laboratory abnormalities (In a clinical trial for the treatment of initial episodes of In 3 clinical trials for the episodic treatment of In a clinical trial for the suppression of recurrent genital herpes infections, the adverse reactions reported by subjects receiving VALTREX 1 gram once daily (n = 269), VALTREX 500 mg once daily (n = 266), or placebo (n = 134), respectively, included headache (35%, 38%, 34%), nausea (11%, 11%, 8%), abdominal pain (11%, 9%, 6%), dysmenorrhea (8%, 5%, 4%), depression (7%, 5%, 5%), In HIV-1−infected subjects, frequently reported adverse reactions for VALTREX (500 mg twice daily; n = 194, median days on therapy = 172) and placebo (n = 99, median days on therapy = 59), respectively, included headache (13%, 8%), fatigue (8%, 5%), and rash (8%, 1%). Acyclovir could be made use of by pregnant females, as it's been categorized as FDA pregnancy classification B (not expected to trigger injury to a coming kid).